Free Trial

Spruce Biosciences (SPRB) Competitors

Spruce Biosciences logo
$150.86 -6.96 (-4.41%)
As of 01:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SPRB vs. DMAC, UPXI, REPL, LRMR, ALT, CADL, ACIU, CTNM, GALT, and TNYA

Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include DiaMedica Therapeutics (DMAC), Upexi (UPXI), Replimune Group (REPL), Larimar Therapeutics (LRMR), Altimmune (ALT), Candel Therapeutics (CADL), AC Immune (ACIU), Contineum Therapeutics (CTNM), Galectin Therapeutics (GALT), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry.

Spruce Biosciences vs. Its Competitors

Spruce Biosciences (NASDAQ:SPRB) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Spruce Biosciences has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

DiaMedica Therapeutics' return on equity of -78.99% beat Spruce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Spruce BiosciencesN/A -177.45% -118.06%
DiaMedica Therapeutics N/A -78.99%-69.94%

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spruce Biosciences presently has a consensus target price of $131.25, suggesting a potential downside of 13.00%. DiaMedica Therapeutics has a consensus target price of $12.33, suggesting a potential upside of 83.94%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Spruce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.13
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Spruce Biosciences had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Spruce Biosciences and 0 mentions for DiaMedica Therapeutics. Spruce Biosciences' average media sentiment score of 0.69 beat DiaMedica Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Spruce Biosciences Positive
DiaMedica Therapeutics Neutral

DiaMedica Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce Biosciences$4.91M17.21-$53.04M-$86.21-1.75
DiaMedica TherapeuticsN/AN/A-$24.44M-$0.69-9.72

Summary

DiaMedica Therapeutics beats Spruce Biosciences on 8 of the 15 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRB vs. The Competition

MetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$84.30M$1.05B$6.17B$10.68B
Dividend YieldN/A4.84%5.72%4.83%
P/E Ratio-1.751.3129.4727.34
Price / Sales17.2130.11587.77132.79
Price / CashN/A17.6325.8230.35
Price / Book2.888.1712.446.68
Net Income-$53.04M-$7.36M$3.32B$276.46M
7 Day Performance-5.12%-0.11%2.15%0.77%
1 Month Performance1,696.23%28.58%8.41%3.73%
1 Year Performance287.58%-12.71%61.67%36.59%

Spruce Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRB
Spruce Biosciences
1.1336 of 5 stars
$150.87
-4.4%
$131.25
-13.0%
+305.4%$84.30M$4.91M-1.7520Gap Down
DMAC
DiaMedica Therapeutics
1.0358 of 5 stars
$7.02
-0.6%
$12.33
+75.7%
+51.6%$359.40MN/A-10.0820
UPXI
Upexi
2.3972 of 5 stars
$6.05
-6.7%
$15.50
+156.3%
+49.6%$351.81M$15.81M0.00130Gap Up
REPL
Replimune Group
3.3469 of 5 stars
$4.50
-1.3%
$6.50
+44.5%
-61.0%$348.54MN/A-1.38210Trending News
Analyst Upgrade
Gap Up
LRMR
Larimar Therapeutics
3.1631 of 5 stars
$4.13
-2.9%
$16.71
+305.2%
-45.9%$344.78MN/A-2.6730
ALT
Altimmune
2.3594 of 5 stars
$3.90
-2.6%
$17.40
+346.4%
-44.3%$340.24M$20K-3.2750Analyst Forecast
CADL
Candel Therapeutics
2.6299 of 5 stars
$6.13
-5.2%
$20.00
+226.2%
-12.0%$335.11M$120K-8.8560
ACIU
AC Immune
1.5677 of 5 stars
$3.27
-5.9%
$10.00
+206.3%
-7.3%$333.36M$31.02M-5.72140
CTNM
Contineum Therapeutics
1.91 of 5 stars
$11.71
-1.9%
$22.20
+89.7%
-28.6%$332.13M$50M-5.3831
GALT
Galectin Therapeutics
1.3307 of 5 stars
$5.09
-0.2%
$6.00
+17.9%
+86.9%$323.18MN/A-7.889News Coverage
Gap Up
TNYA
Tenaya Therapeutics
3.4045 of 5 stars
$2.00
+0.8%
$6.25
+213.3%
-11.3%$321.40MN/A-2.05110Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:SPRB) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners